MA40480B1 - Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie - Google Patents

Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Info

Publication number
MA40480B1
MA40480B1 MA40480A MA40480A MA40480B1 MA 40480 B1 MA40480 B1 MA 40480B1 MA 40480 A MA40480 A MA 40480A MA 40480 A MA40480 A MA 40480A MA 40480 B1 MA40480 B1 MA 40480B1
Authority
MA
Morocco
Prior art keywords
schizophrenia
sustained
crystallization
treatment
release formulations
Prior art date
Application number
MA40480A
Other languages
English (en)
Inventor
Wilfredo Morales Jr
Tarek A Zeidan
Renato A Chiarella
Steven G Wright
Jason M Perry
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MA40480B1 publication Critical patent/MA40480B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne des procédés de production d'injection retard d'aripiprazole lauroxil recristallisé dans lesquels des particules de l'aripiprazole lauroxil ont une surface d'environ 0,50 à environ 3,3 m²/g; et des cristaux d'aripiprazole lauroxil produits par de tels procédés. La présente invention concerne un procédé de fabrication d'un composé de formule (a) sous forme cristalline dans lequel ra est ch20c(o)r et dans lequel r1 est un fragment aliphatique substitué ou non substitué.
MA40480A 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie MA40480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
PCT/US2015/046525 WO2016032950A1 (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Publications (1)

Publication Number Publication Date
MA40480B1 true MA40480B1 (fr) 2021-08-31

Family

ID=55347322

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055917A MA55917A (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
MA40480A MA40480B1 (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055917A MA55917A (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Country Status (19)

Country Link
US (4) US10064859B2 (fr)
EP (2) EP3865476A1 (fr)
JP (2) JP6591546B2 (fr)
CN (2) CN107106556B (fr)
AU (2) AU2015306910B2 (fr)
CA (1) CA2959329C (fr)
CY (1) CY1124058T1 (fr)
DK (1) DK3185867T3 (fr)
ES (1) ES2862098T3 (fr)
HR (1) HRP20210551T1 (fr)
HU (1) HUE054641T2 (fr)
IL (1) IL250661B (fr)
LT (1) LT3185867T (fr)
MA (2) MA55917A (fr)
PL (1) PL3185867T3 (fr)
PT (1) PT3185867T (fr)
RS (1) RS61709B1 (fr)
SI (1) SI3185867T1 (fr)
WO (1) WO2016032950A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
PL3185867T3 (pl) * 2014-08-25 2021-11-22 Alkermes Pharma Ireland Limited Sposób krystalizacji pochodnych arypiprazolu w formulacjach o przedłużonym uwalnianiu do leczenia schizofrenii
WO2016181406A1 (fr) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Procédé amélioré pour la préparation d'aripiprazole doté d'une taille de particule réduite
WO2018104953A1 (fr) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 7-{4-[4-(2,3-dichlorophényl)-pipérazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)méthyl dodécanoate
EP3658540B1 (fr) 2017-07-28 2021-12-01 Interquim, S.A. Procédé de préparation du lauroxil d'aripiprazole
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
DK2445502T4 (da) * 2009-06-25 2022-11-28 Alkermes Pharma Ireland Ltd Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser
WO2012077134A1 (fr) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Méthode de préparation de polymorphes d'aripiprazole
BR112013017506B1 (pt) * 2011-01-07 2021-01-26 Neodyne Biosciences, Inc. montagem de curativo
HUE065359T2 (hu) * 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
CA2867121C (fr) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
US9193685B2 (en) * 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
PL3185867T3 (pl) * 2014-08-25 2021-11-22 Alkermes Pharma Ireland Limited Sposób krystalizacji pochodnych arypiprazolu w formulacjach o przedłużonym uwalnianiu do leczenia schizofrenii

Also Published As

Publication number Publication date
AU2020264303A1 (en) 2020-11-26
HRP20210551T1 (hr) 2021-08-20
AU2015306910A1 (en) 2017-03-16
IL250661B (en) 2020-04-30
EP3185867A1 (fr) 2017-07-05
US10064859B2 (en) 2018-09-04
AU2020264303B2 (en) 2022-10-13
AU2015306910A8 (en) 2020-11-19
JP2017526747A (ja) 2017-09-14
US10973816B2 (en) 2021-04-13
NZ729479A (en) 2021-03-26
CN107106556B (zh) 2020-06-05
US20210205302A1 (en) 2021-07-08
CA2959329A1 (fr) 2016-03-03
MA55917A (fr) 2022-03-16
CY1124058T1 (el) 2022-05-27
JP6591546B2 (ja) 2019-10-16
PL3185867T3 (pl) 2021-11-22
US20160051546A1 (en) 2016-02-25
DK3185867T3 (da) 2021-03-15
RS61709B1 (sr) 2021-05-31
EP3185867B1 (fr) 2021-01-13
US11883394B2 (en) 2024-01-30
ES2862098T3 (es) 2021-10-07
CA2959329C (fr) 2023-06-27
JP2019210296A (ja) 2019-12-12
US20200108063A1 (en) 2020-04-09
PT3185867T (pt) 2021-04-12
WO2016032950A1 (fr) 2016-03-03
EP3865476A1 (fr) 2021-08-18
LT3185867T (lt) 2021-06-10
AU2015306910B2 (en) 2020-11-19
HUE054641T2 (hu) 2021-09-28
US20190015408A1 (en) 2019-01-17
CN107106556A (zh) 2017-08-29
IL250661A0 (en) 2017-04-30
CN111454207A (zh) 2020-07-28
SI3185867T1 (sl) 2021-08-31
EP3185867A4 (fr) 2018-01-24
US10478434B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
MA40480B1 (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
EP4365179A3 (fr) Nouveaux dérivés de rapamycine
JP2020511461A5 (fr)
MA48798B1 (fr) Procédé de production d'ozanimod
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
MA39205A1 (fr) Polymères contenant des amines primaires utiles en tant qu'inhibiteurs de tartre
JP2020502089A5 (fr)
WO2020016847A3 (fr) Procédé de purification pour la préparation d'éribuline et de ses intermédiaires
HRP20201402T1 (hr) Spojevi inhibitora acetilkolinsteraze i agonisti serotonergičkih receptora 5ht4, s promnezijskim učinkom, postupci za njihovu pripremu i farmaceutski pripravci koji ih sadržavaju
JP2019523279A5 (fr)
CU20210007A7 (es) Derivados de aril-n-arilo para el tratamiento de una infección por virus de ácido ribonucleico (arn)
MX2021000089A (es) Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn).
EA201891095A1 (ru) Альфа-сложные аминоэфиры производного гидроксипропилтиазолидин карбоксамида и его солевая форма, кристаллический полиморф
WO2020132471A8 (fr) Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MA41186B1 (fr) Nouvelles formes de cristal du sel monosodique de foramsulfuron